Van ECK Associates Corp Has $31,000 Stake in Azenta, Inc. (NASDAQ:AZTA)

Van ECK Associates Corp decreased its stake in shares of Azenta, Inc. (NASDAQ:AZTA) by 39.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 636 shares of the company’s stock after selling 412 shares during the quarter. Van ECK Associates Corp’s holdings in Azenta were worth $31,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Hantz Financial Services Inc. bought a new position in Azenta during the second quarter valued at about $30,000. Farther Finance Advisors LLC increased its position in shares of Azenta by 20.0% during the third quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock valued at $74,000 after purchasing an additional 256 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in shares of Azenta by 150.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock valued at $84,000 after purchasing an additional 955 shares in the last quarter. Lazard Asset Management LLC bought a new position in Azenta in the first quarter worth $130,000. Finally, Acadian Asset Management LLC lifted its position in Azenta by 24.7% in the first quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock worth $143,000 after purchasing an additional 471 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.

Insider Activity

In other news, CFO Herman Cueto sold 1,595 shares of the firm’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $43.68, for a total value of $69,669.60. Following the completion of the sale, the chief financial officer now directly owns 24,604 shares in the company, valued at approximately $1,074,702.72. This trade represents a 6.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.77% of the stock is currently owned by corporate insiders.

Azenta Stock Performance

Shares of NASDAQ AZTA opened at $42.63 on Friday. Azenta, Inc. has a 52-week low of $40.24 and a 52-week high of $69.16. The business has a fifty day moving average of $45.68 and a two-hundred day moving average of $50.54. The stock has a market cap of $2.09 billion, a PE ratio of -14.35 and a beta of 1.48.

Azenta (NASDAQ:AZTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.08. The firm had revenue of $170.00 million during the quarter, compared to the consensus estimate of $169.66 million. Azenta had a negative net margin of 25.01% and a positive return on equity of 0.98%. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm posted $0.13 EPS. Analysts predict that Azenta, Inc. will post 0.42 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AZTA. Evercore ISI dropped their price objective on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Needham & Company LLC lowered their target price on shares of Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Azenta has an average rating of “Hold” and a consensus price target of $63.60.

About Azenta

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.